[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339568-105":59,"doc-detail-339568-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","low-bcl-xl-expression-in-triple-negative-breast-cancer-cells-favors-chemotherapy-efficacy-and-this-effect-is-limited-by-cancer-associated-fibroblasts","Low BCL-xL expression in triple-negative breast cancer cells favors chemotherapy efficacy, and this effect is limited by cancer-associated fibroblasts","","Triple-negative breast cancers (TNBC) resist chemotherapy, in part because anti-apoptotic BCL-2 family members such as BCL-xL, MCL-1 and BCL-2 suppress pro-apoptotic protein activation. This work examines how chemotherapy sensitivity of TNBC cells and regulation by cancer-associated fibroblasts (CAFs) shape treatment response. Using gene editing or BH3 mimetics in MDA-MB-231 cells, BCL-xL and MCL-1 promote survival via compensatory mechanisms. BCL-xL depletion or inhibition increases chemotherapy effectiveness, but CAFs still confer a strong pro-survival effect, limiting chemosensitivity even when BCL-xL is reduced.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/low-bcl-xl-expression-in-triple-negative-breast-cancer-cells-favors-chemotherapy-efficacy-and-this-effect-is-limited-by-cancer-associated-fibroblasts/339568/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/low-bcl-xl-expression-in-triple-negative-breast-cancer-cells-favors-chemotherapy-efficacy-and-this-effect-is-limited-by-cancer-associated-fibroblasts/339568.png","ImageObject",300,407,{"name":92,"@type":93},"Maeve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why do triple-negative breast cancers often show poor chemotherapy response?","Question",{"text":112,"@type":113},"TNBC has poor prognosis largely because it resists chemotherapy. Resistance is linked to elevated anti-apoptotic BCL-2 family proteins that block pro-apoptotic activation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the role of BCL-xL in chemotherapy response in TNBC cells?",{"text":117,"@type":113},"BCL-xL is pivotal for therapy response. Depleting or pharmacologically inhibiting BCL-xL increases chemotherapy effectiveness, including effects observed in patient-derived tumoroids.",{"name":119,"@type":110,"acceptedAnswer":120},"How do cancer-associated fibroblasts affect chemotherapy sensitivity?",{"text":121,"@type":113},"In co-culture, CAFs protect TNBC cells from chemotherapy even when BCL-xL reduced expression makes cancer cells more susceptible. CAFs therefore exert a strong pro-survival effect that limits chemosensitivity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},339568,1790440745,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},5909877438554,"https://ap-avatar.wpscdn.com/avatar/5600025385ad2bf12a7?_k=1778553567797529272","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nLow BCL‑xL expression in triple‑negative breast cancer cells favors chemotherapy efficacy, and this effect is limited by cancer‑associated fibroblasts  \nLisa Nocquet1,2,3, Julie Roul 1,2,3,4, Chloé C. Lefebvre1,2,3, Laurine Duarte1,2,3, Mario Campone1,3,4, Philippe P. Juin1,2,3,4* & Frédérique Souazé1,2,3*  \nTriple negative breast cancers (TNBC) present a poor prognosis primarily due to their resistance to chemotherapy. This resistance is known to be associated with elevated expression of certain anti‑ apoptotic members within the proteins of the BCL‑2 family (namely BCL‑xL, MCL‑1 and BCL‑2). These regulate cell death by inhibiting pro‑apoptotic protein activation through binding and sequestration and they can be selectively antagonized by BH3 mimetics. Yet the individual influences of BCL‑xL, MCL‑1, and BCL‑2 on the sensitivity ofTNBC cells to chemotherapy, and their regulation by cancer‑ associated fibroblasts (CAFs), major components of the tumor stroma and key contributors to therapy resistance remain to be delineated. Using gene editing or BH3 mimetics to inhibit anti‑apoptotic BCL‑2 family proteins inTNBC line MDA‑MB‑231, we showthat BCL‑xL and MCL‑1 promote cancer cell survival through compensatory mechanisms. This cell line shows limited sensitivity to chemotherapy, in line with the clinical resistance observed inTNBC patients. We elucidate that BCL‑xL plays a pivotal role in therapy response, as its depletion or pharmacological inhibition heightened chemotherapy effectiveness. Moreover, BCL‑xL expression is associated with chemotherapy resistance inpatient‑derived tumoroids where its pharmacological inhibition enhances ex vivo response to chemotherapy. In a co‑culture model of cancer cells and CAFs, we observe that even in a context where BCL‑xL reduced expression renders cancer cells more susceptible to chemotherapy, those in contact with CAFs display reduced sensitivity to chemotherapy. Thus CAFs exert a profound pro‑survival effect in breast cancer cells, even in a setting highly favoring cell death through combined chemotherapy and absence of the main actor of chemoresistance, BCL‑xL.  \nKeywords Apoptosis, Breast cancer, Cancer-associated fibroblasts, BCL-2 family, Chemotherapy  \nTriple negative breast cancer (TNBC), characterized by the lack of expression of hormonal receptors and the absence ofErb2 amplification, is associated with a poor prognosis due to its aggressive nature and the absence of effective targeted treatments. Consequently, TNBC treatment is often limited to non-targeted chemotherapy, which may not be sufficient to eliminate cancer cells1,2. The limited effectiveness of therapy and the development of drug resistance in TNBC is in great part related to pathways regulating mitochondrial outer membrane permeabilization (MOMP). Many anticancer drugs commonly used in clinical practice rely on this mitochondria disrupting event to induce cancer cell death3. The BCL-2 family proteins play a crucial role in MOMP, which leads to the release of cytochrome c into the cytoplasm and the activation of a caspase cascade and subsequent cell death through canonical apoptosis or other cell death modes. Cancer cells can survive by altering the balance between anti-apoptotic and pro-apoptotic members of the BCL-2 family4. Numerous studies have demonstrated that elevated levels of pro-survival proteins, including BCL-xL, MCL-1, and BCL-2, are frequently observed in cancers and contribute to drug resistance5. BCL-xL and MCL-1 are notably overexpressed in TNBC cells compared to normal counterpart6–8. BH3 mimetics, a class of small compounds, antagonize binding of BCL-2  \n1INSERM, CNRS, CRCI2NA, Université de Nantes, 44000 Nantes, France. 2Equipe Labellisée LIGUE Contre le Cancer, Paris, France. 3SIRIC ILIAD, Nantes, Angers, France. 4ICO René Gauducheau, Saint Herblain, France.* email: [philippe.juin@univ-nantes.fr](philippe.juin@univ-nantes","cbCaid1NxCfoJrH7","https://ap.wps.com/l/cbCaid1NxCfoJrH7","pdf",3476201,"English","# Abstract\n## Background: BCL-2 family and TNBC chemotherapy resistance\n## Experimental approach: gene editing and BH3 mimetics\n## Key findings: roles of BCL-xL and MCL-1\n## Influence of CAFs on therapy response\n## Implications for therapeutic strategies","[{\"question\":\"Why do triple-negative breast cancers often show poor chemotherapy response?\",\"answer\":\"TNBC has poor prognosis largely because it resists chemotherapy. Resistance is linked to elevated anti-apoptotic BCL-2 family proteins that block pro-apoptotic activation.\"},{\"question\":\"What is the role of BCL-xL in chemotherapy response in TNBC cells?\",\"answer\":\"BCL-xL is pivotal for therapy response. Depleting or pharmacologically inhibiting BCL-xL increases chemotherapy effectiveness, including effects observed in patient-derived tumoroids.\"},{\"question\":\"How do cancer-associated fibroblasts affect chemotherapy sensitivity?\",\"answer\":\"In co-culture, CAFs protect TNBC cells from chemotherapy even when BCL-xL reduced expression makes cancer cells more susceptible. CAFs therefore exert a strong pro-survival effect that limits chemosensitivity.\"}]","Low BCL-xL expression in triple-negative breast cancer cells favors chemotherapy efficacy, and this effect is limited by cancer-associated fibroblasts | PDF",1790031027,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d2c152e53d4b80825341708f0d634b90.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4367afe240f3348719e7f2691ac551d9.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/18ff7846ce1400fcbd34ce62c87235d0.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/976e9ca80f10ad93cdbb7bc00e1d9a48.webp",980,1287]